Gastric cancer in the era of immune checkpoint blockade by Figueroa Protti, Lucía et al.
Review Article
Gastric Cancer in the Era of Immune Checkpoint Blockade
Lucı´a Figueroa-Protti ,1,2,3 Rebeca Soto-Molinari ,1,3 Melany Caldero´n-Osorno ,3
Javier Mora ,2,4 and Warner Alpı´zar-Alpı´zar 1,3,5
1Research Center in Microscopic Structures (CIEMIC), University of Costa Rica, San Jose´ 2060, Costa Rica
2Department of Parasitology, Faculty of Microbiology, University of Costa Rica, San Jose´ 2060, Costa Rica
3Cancer Epidemiology Research Program (INISA), Health Research Institute, University of Costa Rica, San Jose´ 2060, Costa Rica
4Research Center in Tropical Diseases (CIET), University of Costa Rica, San Jose´ 2060, Costa Rica
5Department of Biochemistry, Faculty of Medicine, University of Costa Rica, San Jose´ 2060, Costa Rica
Correspondence should be addressed to Warner Alpı´zar-Alpı´zar; warner.alpizar@ucr.ac.cr
Received 25 May 2019; Accepted 22 August 2019; Published 24 September 2019
Guest Editor: Nathaniel Weygant
Copyright © 2019 Luc´ıa Figueroa-Protti et al. -is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Gastric cancer (GC) is one of the most important malignancies worldwide because of its high incidence and mortality. -e very
low survival rates are mainly related to late diagnosis and limited treatment options. GC is the final clinical outcome of a stepwise
process that starts with a chronic and sustained inflammatory reaction mounted in response to Helicobacter pylori infection. -e
bacteriummodulates innate and adaptive immunity presumably as part of the strategies to survive, which favors the creation of an
immunosuppressive microenvironment that ultimately facilitates GC progression. T-cell exhaustion, which is characterized by
elevated expression of immune checkpoint (IC) proteins, is one of the most salient manifestations of immunosuppressive
microenvironments. It has been consistently demonstrated that the tumor-immune microenvironment(TIME)-exhausted
phenotype can be reverted by blocking ICs with monoclonal antibodies. Although these therapies are associated with long-lasting
response rates, only a subset of patients derive clinical benefit, which varies according to tumor site. -e search for biomarkers to
predict the response to IC inhibition is a matter of intense investigation as this may contribute to maximize disease control, reduce
side effects, and minimize cost. -e approval of pembrolizumab for its use in GC has rocketed immuno-oncology research in this
cancer type. In this review, we summarize the current knowledge centered around the immune contexture and recent findings in
connection with IC inhibition in GC.
1. Introduction
Inflammation is an intrinsic feature of cancer, influencing
many processes that take place during tumor development
and progression [1–3]. In fact, tumor growth is severely
compromised if neoplastic cells are not immersed in an
appropriate microenvironment in which neoplastic, im-
mune, and other nonimmune stromal cells coexist [4, 5].
-is tumor niche is constantly being reshaped as a result of
heterotypic signaling between neoplastic and nonneoplastic
cells. Given the relevance of the immune contexture in
cancer, we are currently witnessing a change of paradigm in
cancer therapy, traditionally focused on cancer cells, with the
emergence of therapies centered around the TIME [6, 7].
Immune-checkpoint blockade (ICB) is currently at the lead
and profiled as the most promising immunotherapeutic
approach in cancer [8–10]; however, despite the very en-
couraging results in some types of cancer, only a subset of
patients obtain clinical benefit from ICB. One of the major
challenges is, therefore, the identification of precise and
accurate biomarkers to personalize ICB in the clinic. Very
likely, predictive biomarkers need to be contextualized to
each histology [11].
Infection and chronic inflammation are key players in
the pathogenesis of GC. H. pylori infection, which is par-
ticularly linked to GC of intestinal subtype, the most
commonly diagnosed worldwide, triggers chronic and
persistent inflammation of the gastric mucosa, characterized
by intramural infiltration of inflammatory cells and ex-
pression of a vast array of inflammatory mediators [12].
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Epstein–Barr virus (EBV) is also associated with the etiology
of approximately 10% of the GC cases, especially those
located in the proximal stomach [13]. Infiltration of the
tumor with CD8+ T cells is a common feature of the EBV+
GC [14]. Environmental and genetic determinants are also
implicated in the genesis of this malignancy. -us, the
complex interplay of environment, genetics, infection, and
inflammation translates into a very heterogeneous disease at
the molecular level [14], which ultimately has an impact in
the clinical management of the GC patients.
In 2017, the FDA approved the use of the anti-
programmed cell death protein 1 (PD-1), pembrolizumab, in
advanced or recurrent GC expressing programmed cell
death 1 ligand 1 (PD-L1) [15]. Even before this, various
studies had investigated the expression of the PD1/PD-L1
axis in GC, and several found correlation between PD-L1
expression and clinicopathological parameters, including
patient survival [16–21]. Interestingly, some reports indicate
that H. pylori induces the expression of PD-L1 [22–25]. In
addition to PD-L1, several other parameters currently
suggested as biomarkers of potential clinical relevance for
predicting the response to ICB are being studied in GC. In
this review, we provide a summary of the current knowledge
centered around the immune contexture and the main
findings obtained so far in connection to ICB and predictive
biomarkers in GC.
2. Epidemiology
GC is one of the most important malignancies worldwide. In
2018, this neoplasm accounted for approximately 1,000,000
new cases and 780,000 deaths globally, which makes it the
fifth most commonly diagnosed and the third cause of
cancer death [26]. Incidence and mortality rates present
substantial variations according to geographic location, with
well-defined high- and low-risk areas across the world. More
specifically, gastric malignancy is highly incident in Eastern
Asia, Eastern Europe, and countries located in the Pacific
coast of Latin America; in contrast, incidence rates are
generally low in Northern America, Northern Europe,
Southern Asia, and Australia [27–29]. Mortality rates also
show variations with a very similar geographical pattern
[27–29]. Interestingly, incidence and mortality rates are 2-
fold higher in men than in women [27].
In the last decades, GC incidence rates are experiencing a
steady decline globally [27, 29]. Although the reasons remain
obscure, it is speculated that this is at least partially at-
tributed to the concomitant decrease inH. pylori prevalence,
which is a very well-established factor related to the path-
ogenesis of GC (discussed below). -e decrease, however, is
not of the same magnitude in GC of different histological
subtypes or anatomical locations [27, 30]. -e declining
trend is particularly connected to a decrease in the incidence
of intestinal subtype, whereas the diffuse subtype remains
more or less stable [31, 32]. Similarly, GC of the lower part of
the stomach is becoming less common, while the rate of
cancer of the gastric cardia is increasing, particularly in high-
income countries [27, 30, 32]. Although mortality rates also
show a global decline, GC is still one of the most important
causes of cancer death [27, 29]. At least in some countries,
this downward trend inmortality may be partially connected
to the implementation of population-based early-screening
programs [33–35]. Nonetheless, the 5-year survival rate
remains below 30% in most countries, which is mainly
related to the fact that most of the cases are diagnosed at
advanced stages, when treatment is likely to fail [36]. Studies
in population groups with the same ethnic background but
dissimilar access to health care, however, suggest that bi-
ological factors could also contribute to explain themortality
and survival of GC [37].
3. Histopathology
GC is classified, among other factors, according to histo-
pathological characteristics and anatomic location. -e
Lauren histological classification system is probably the most
used and categorizes gastric adenocarcinomas into threemain
histologic types: intestinal, diffuse, and mixed [38]. Impor-
tantly, Lauren histological subtypes show substantial differ-
ences at the epidemiological, pathological, and molecular
levels [38–41]. Anatomical location of the malignant lesions is
also an important parameter in the classification of GC.
Marked epidemiological and etiological differences have been
revealed for malignant tumors located in the distal part of the
stomach and those of the most proximal region [42–44].
4. Pathogenesis
-e pathogenesis of GC is complex and multifactorial, and
differs substantially depending on the histological and an-
atomical subtype. GC of intestinal subtype, for instance, is
the final clinical outcome of a stepwise process known as the
Correa Cascade [45]. It starts with H. pylori colonization of
the normal gastric mucosa, which in conjunction with en-
vironmental insults (i.e., diet and lifestyle) triggers a sus-
tained inflammatory reaction resulting in chronic gastritis
that, in some patients, may progress to multifocal atrophic
gastritis. A subset of themmay develop intestinal metaplasia,
dysplasia, and ultimately invasive carcinoma [46]. Much less
is known about the pathogenesis of the diffuse subtype of GC
[47, 48].
Despite the very well-established role of H. pylori in
gastric carcinogenesis, most of the infected individuals re-
main asymptomatic or even develop pathologies not related
to GC [49]. -is feature actually represents one of the most
intriguing paradoxes about this bacterial infection. Bacterial
strains exhibiting enhanced molecular virulence that ulti-
mately result in stronger inflammatory response are con-
sistently associated with even higher risk of GC [50–52].
Also, a number of polymorphic variants in genes encoding
proinflammatory and anti-inflammatory cytokines that play
an important role in the immune response triggered by
H. pylori are also linked to the GC pathogenesis [53–55].
-us, it is the combination of bacterial, host, and envi-
ronmental factors what presumably determines the final
clinical outcome.
Although the pathogenesis of the malignant lesions
arising in the proximal stomach remains very enigmatic
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[56], EBV is presumably an important etiological factor for
tumors at this particular location, especially those located in
the cardia and fundus [13]. EBV-positive tumors constitute
around 10% of the cases and, given their very distinctive
features, they are actually regarded as a different molecular
subtype [13, 14].
5. Tumor-Immune Contexture in
Gastric Cancer
Immune contexture is recognized as a crucial determinant of
cancer [1, 57]. Infiltrating immune cells including macro-
phages, neutrophils, dendritic cells, and several lineages of
T cells are major constituents of the tumor microenviron-
ment, participating in many processes that take place during
cancer initiation and growth [2, 5].
In general, the TIME of overt GC lesions shows an
immunosuppressive character (Figure 1(c)). -is, however,
may vary according to parameters such as tumor histology,
anatomical location of the lesion, and molecular subtype, as
recently revealed [58]. According to this study, in general,
the most prevalent tumor-infiltrating leukocytes were
CD8+ T cells, CD68+ macrophages, and CD4+ T cells,
representing 15%, 13%, and 11% of all intratumoral cells,
respectively. When subdivided according to subtypes, the
infiltration with CD8+ T cells, CD4+ T cells, and macro-
phages was particularly elevated in the EBV+ tumors and the
least infiltrated corresponded to the GCs of diffuse subtype.
Interestingly, the presence of infiltrating macrophages in GC
of intestinal subtype was markedly conspicuous and that of
Tcells in general was relatively low. Finally, the prevalence of
FOXP3+ Tregs in GC was dismal, regardless of the histologic
or molecular subtype [58]. Although the latter is probably
the most comprehensive, a substantial number of studies
have also assessed the composition of the TIME in GC (due
to space limitations, we only cite some) [59–69]. Variations
in the general prevalence of leukocytes and lymphocytes
between studies are expected as a result of the number of
patients included, the fact that not all take into account the
same clinicopathological and molecular features and the
methodological approach used for profiling the immune cell
composition and the study design. A general trend, however,
in the studies performed so far, is that EBV+ GCs are the
most infiltrated tumors, especially by CD8+ T cells. Also,
many of the studies have found a significant association
between the high number of tumor-infiltrating lymphocytes
and improved overall survival, which is particularly robust
for the CD8+ T cells [59, 61, 70, 71]. Unlike other types
of cancer, there is no current consensus on the morpho-
logic evaluation of tumor-infiltrating lymphocytes in
GC, despite some attempts [59]. -erefore, the standardi-
zation of a scoring method for quantitation of the tumor-
infiltrating lymphocytes in GC lesions is highly needed.
6. Immune Exhaustion
T-cell exhaustion was first defined in chronic infections as
the failure of effector T cells to acquire a memory T-cell
homeostatic state [72]. During an acute infection, a great
portion of activated T cells die after the peak of effector
expansion; however, a subset persists losing its effector
functions and becoming part of the memory T-cell pool. By
contrast, in chronic infections, the ongoing antigen stim-
ulation and persistent inflammation induce a progressive
loss of effector T-cell functions, but failing to acquire the
antigen-independent memory state [72]. One of the most
important features of the T-cell exhaustion phenomenon is
the progressive increase in the amount and diversity of
inhibitory receptors expressed on T cells, including PD-1,
cytotoxic T-lymphocyte antigen-4 (CTLA-4), lymphocyte-
activation gene 3 protein (LAG-3), T-cell immunoglobulin
domain and mucin domain (TIM-3), 2B4, CD160, V-do-
main Ig suppressor of T-cell activation (VISTA), and T-cell
immunoreceptor with immunoglobulin and ITIM domains
(TIGIT) [72–74]. Under physiological conditions, these
inhibitory receptors, also called ICs, have a crucial role
activating negative regulatory pathways in order to prevent
autoreactivity and the subsequent immunopathological
tissue damage [75]. After T-cell activation, these inhibitory
molecules are expressed transiently in functional effector
T cells thus maintaining an adequate balance of the im-
mune process [72]. During T-cell exhaustion, however, IC
proteins are highly and steadily expressed, and the exhausted
phenotype severity depends on the level and number of
inhibitory receptors [72].
Although T-cell exhaustion was originally defined in
chronic infection, a similar dysfunctional state has been
observed in cancer [73]. -e role of the immune system in
tumor initiation and progression has been widely explored.
In fact, the immune-mediated mechanisms play a pivotal
role in all stages of tumor biology, regardless of the tissue
origin of the tumors. Importantly, the immune system poses
a strong selective pressure on the tumor mass that ultimately
shapes tumor growth, which has led to the proposal of a
cancer-immunoediting process. More specifically, the im-
mune system proceeds sequentially through three distinct
phases during tumor development: (1) elimination, in which
the innate and adaptive immune systems work together to
detect the presence of potentially malignant cells, activate
against them, andmediate their destruction; (2) equilibrium,
where rare tumor cell variants survive the elimination phase,
but the adaptive immune system still prevents their out-
growth and maintains them at bay; (3) escape, in which
tumor cells that have acquired the ability to circumvent
immune recognition emerge as progressively growing tu-
mors [76]. -is last phase can occur through two principal
mechanisms: the generation of poorly immunogenic tumor
cell variants that are “invisible” to the immune system and/
or the establishment of an immunosuppressive state within
the tumor microenvironment, which includes the induction
of T-cell exhaustion [76]. As a general rule, the inhibitory
ligands and receptors that regulate T-cell effector functions
in tissues are commonly overexpressed in tumor cells or in
nonneoplastic cells in the tumor microenvironment [75].
T-cell exhaustion in cancer and chronic infection share
many commonalities, including reduced proinflammatory
cytokine production, impaired cytotoxic activity, and elevated
levels of multiple inhibitory receptors. Notwithstanding this,
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differences are also appreciated. In cancer, for instance,
priming to tumor antigens is more likely to occur in the
absence of inflammation. Consequently, na¨ıve tumor-specific
T cells may fail to become properly activated and never dif-
ferentiate into effector T cells, thus acquiring directly a T-cell
exhaustion phenotype [73]. Also, tolerance mechanisms could
shape T-cell responses to favor mainly lower-affinity clones
[73].
Another important factor influencing intratumoral
T-cell activity is the metabolic state of the tumor micro-
environment. Effector T cells activate glycolytic pathways
for ATP production, even in the presence of oxygen, in a
HIF-1α-dependent manner [77, 78]. Glucose metabolism in
T cells is promoted by HIF-1α and the AKT/mTOR path-
way, which in turn induces the upregulation of glucose
transporter GLUT1, providing the T cells enough energy to
perform their effector functions [79]. Tumor cells also re-
program their metabolic pathways towards glycolysis, which
is mediated by hypoxia and HIF-1α. -e fact that
proliferating tumor cells increase their glucose uptake limits
its availability for T cells as an energy source for their ef-
fector functions, affecting the antitumor immune response
[80]. Besides changes in the glucose availability in the tumor
microenvironment, intrinsic factors in the T cells affect
their metabolism. For instance, GC cells express ligands to
ICs, such as PD-L1 and CD155, which induce T-cell ex-
haustion after interacting with PD-1 and TIGIT of the
surface of Tcells, respectively (Figure 1(c)). PD-1 and TIGIT
expression affect T-cell metabolism by inhibiting glycolysis
and limiting their effector functions [81, 82]. In fact,
downregulation in the expression levels of genes encoding
proteins involved in glucose uptake, glucose metabolism,
and the AKT/mTOR pathway has been observed in TIGIT+
CD8 T cells from GC patients. Mechanistically, this effect
was induced after TIGIT interaction with CD155. In-
terestingly, the T-cell exhausted phenotype was reversed
when the uptake of glucose was increased. Additionally,
TIGIT blockade alone or in combination with PD-1
Proinflammatory response
(a)
(b)
(c)
(d)
Figure 1: Immune contexture in the pathogenesis of gastric cancer. (a)-e colonization ofH. pylori in the normal gastric mucosa triggers an
inflammatory response with accumulation of neutrophils and inflammatory macrophages and production of proinflammatory cytokines
such as IL-1β, IL-8, IL-6, and TNF-α; leading to -1 polarization, IFN-c production, and chronic gastritis. (b) In later stages, H. pylori
induces the overexpression of PD-L1 in epithelial cells of the gastric mucosa as an immune evasion mechanism, characterized by an increase
in regulatory T cells, myeloid-derived suppressor cells (MDSCs), and IL-10 production. (c) Gastric cancer cells express PD-L1 and CD155
which after interacting with PD-1 and TIGITon the surface of cytotoxic Tcells induce T-cell exhaustion and promote the development of an
anti-inflammatory tumor microenvironment. (d) Epstein–Barr virus- (EBV-) positive gastric cancer lesions are mainly located in the
proximal stomach and are characterized by amplification and, consequently, high PD-L1 and PD-L2 expression with a prominent immune
cell infiltration (created with BioRender.com).
4 Journal of Oncology
inhibitors improves antitumor immunity in an animal
model of GC [82].
As in many other types of cancer, IC overexpression has
been described in GC as a mechanism for T-cell exhaustion.
Since 2000s, several studies have explored the role of PD-1
and PD-L1 expression in the TIME of GC. More recently,
upregulation of other ICs such as CTLA-4, TIM-3, and
VISTA has also been reported in human GC [83–85].
Nevertheless, the clinical significance of the differential
expression of these immunomodulatory molecules among
GC patients has not yet been completely elucidated.
7. Immune-Checkpoint Blockade in
Gastric Cancer
-e description of the T-cell exhaustion phenomenon in the
context of cancer and its role in promoting tumor growth led
to a paradigm shift in cancer treatment the past decade. -e
new vision of tumor therapy has focused in the development
of approaches that intend to target or manipulate the im-
mune system in order to reactivate antitumor T-cell func-
tions. One of the most significant breakthroughs so far is the
pharmacological blockade of PD-1/PD-L1 and CTLA-4 as
novel immunotherapeutic options, which reverses T-cell
exhaustion and unleashes strong antitumor immune re-
sponses. Importantly, the fact that PD-1/PD-L1 inhibition
leads to a reduction in tumor load shows that T-cell ex-
haustion is not a terminally dysfunctional state and that an
active and effective antitumor immune response can be
restored [73, 75].
-e FDA approval of the IC inhibitors pembrolizumab
and nivolumab for the treatment of melanoma in 2014
initiated a new era in the treatment of cancer. Since then, a
number of PD-1/PD-L1 and CTLA-4 inhibitors have been
approved for the treatment of several cancer types, andmany
clinical trials are currently running [6]. Specifically for GC,
the anti-PD-1, pembrolizumab, was approved by FDA in
2017 for its use in advanced, recurrent GC expressing PD-L1,
which was based on the phase II KEYNOTE-059 clinical trial
[21]. At present, several clinical trials are evaluating other IC
inhibitors, including the anti-PD-1 nivolumab, the anti-PD-
L1 avelumab, durvalumab, and atezolizumab, and anti-
CTLA4 ipilimumab and tremelimumab. In Supplementary
Table 1, we summarize the most representative clinical trials
evaluating the safety and efficacy of PD-1/PD-L1 inhibitors
in GC. Further details of all ICB clinical trials in GC can be
found elsewhere [86, 87]. Of note, the phase II trial ONO-
4538 and phase III trial ATTRACTION-2 revealed that
nivolumab administration to heavily pretreated GC patients
is associated with improved overall survival, compared to
patients treated with placebo. -ese results led to the ap-
proval of nivolumab in Japan for the treatment of advanced-
stage GC patients progressing after standard systemic cy-
totoxic therapy, regardless of the PD-L1 status [88]. Some of
the current trials in GC are evaluating combinations of PD-
1/PD-L1 inhibitors with conventional therapies. -e
MORPHEUS-GC trial, for example, has eight different study
groups that combine IC inhibitors, chemotherapeutic
agents, MEK inhibitors, anti-VEGF receptor 2 antibodies,
PEGylated recombinant human hyaluronidase, CXCR4
antagonists, and DDP-4 inhibitors [86, 87]. Also, the
CIRCUIT trail combines ICB therapy with neoadjuvant
short-term-limited local radiotherapy [87]. Combinations of
IC inhibitors are also being evaluated in GC. -e latter is
based on previous studies performed in other cancer types
showing that combination of two IC blockers leads to sig-
nificantly improved response rates. In fact, an ongoing phase
I/II trial is analyzing the safety and efficacy of nivolumab
plus ipilimumab, compared to nivolumab alone, in patients
with chemotherapy refractory GC [86, 87].
Other IC proteins are currently studied in preclinical and
clinical settings as potential therapeutic targets in cancer,
including LAG-3, TIM-3, and TIGIT [6]. In GC patients, for
example, TIM-3 and Gal-9 expressions have been associated
with poor patient overall survival, suggesting an important
role of these molecules in T-cell exhaustion [89]. Further-
more, the potential of LAG-3 as therapeutic target in GC was
recently demonstrated in a mouse model using recombinant
soluble LAG-3. More specifically, administration of
recombinant soluble LAG-3 reduces tumor growth, en-
hances the secretion of interferon (IFN)-c, promotes CD8+
T-cell activation, and increases the survival rate of GC-
bearing mice [90]. In this line, the FRACTION-GC trial
seeks to further explore the potential of LAG-3 as a novel
therapeutic target by including a group of cancer patients
who will receive nivolumab plus an anti-LAG-3 antibody
[86, 87].
8. Immune-Checkpoint Blockade-Predictive
Biomarkers in Gastric Cancer
Cancer patients that respond to ICB generally have long-
lasting response rates and manageable safety profile. -is,
however, is eclipsed by the fact that only a subset of patients
derive clinical benefit, which varies according to tumor site.
-erefore, the search for biomarkers that can be used in
clinical practice to predict the response to ICB is a matter of
intense investigation as this may contribute to maximize
disease control, reduce side effects, and minimize cost. To
date, parameters such as the elevated expression of IC
proteins, high mutational load, mismatch repair (MMR)
deficiency, microsatellite instability (MSI), high density of
infiltrating CD8+ T cells in tumor lesions, and presentation
of neoantigens of viral origin are emerging as potential
predictive biomarkers [47, 48, 91–96]. Intriguingly, a frac-
tion of patients regarded as potential responders according
to these biomarkers do not respond to ICB, which suggest
that some parameters of relevance for predicting the re-
sponse to such agents are still unknown. For instance,
studies in melanoma have revealed that the composition and
diversity of the gastrointestinal microbiota differ between
responders to IC inhibition and nonresponders [97, 98],
which is recapitulated in mouse models [99, 100]. An ex-
cellent review on ICB predictive biomarkers in cancer has
been recently published [101].
A substantial number of studies have characterized the
expression pattern of PD-L1 in GC and its correlation with
clinicopathological variables. According to these studies,
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PD-L1 is expressed in 25 to 65% of GC patients, and it is
associated with tumor size, lymph node metastasis, and
shorter overall survival [18]. Although it has been widely
used as companion test in a large number of clinical studies,
its utility as a biomarker has been questioned because not all
PD-L1+ patients respond to ICB and, even more in-
triguingly, some negative patients do respond (Supple-
mentary Table 1). -is may be influenced by the lack of a
universal cutoff point, differences in the PD-L1 detection
assays used, and spatiotemporal intratumor heterogeneity.
Many clinical studies using PD-L1 as companion test rely on
PD-L1 expression in tumor cells only [8, 9]. More recently,
at least in GC, the so-called combined positive score (CPS),
which takes into account the PD-L1 positivity on cancer and
infiltrating immune cells, has been adopted. -is actually
showed to be a better scoring method than the percentage of
PD-L1+ tumor cells in the KEYNOTE-059 clinical trial with
GC patients [70]. Often, clinical trials in GC use a CPS ≥1;
nevertheless, it still fails to accurately stratify patients who
will benefit from ICB. In the KEYNOTE-061 trial, a CPS ≥10
was evaluated and the overall survival of GC patients treated
with pembrolizumab was longer than that of patients under
chemotherapy, which could not be recapitulated with a CPS≥1 (Supplementary Table 1). -ese results support the no-
tion that the semiquantitative counting of PD-L1 expression
needs to be further refined.
MSI is probably one of the most promising predictive
biomarkers for ICB. In fact, FDA approved the use of
pembrolizumab in patients with unresectable or metastatic
solid tumors with MSI or MMR deficiency, regardless of its
tissue of origin. -is was actually the first time that FDA
approved a cancer treatment based on a common biomarker
rather than the location of the tumor. Several of the clinical
studies performed in GC have added even more evidence that
justifies its use as companion test (Supplementary Table 1).
Interestingly, in the NCT02589496 trial [102], the only GC
patient with highMSI that did not respond to pembrolizumab
treatment had a heterogeneous MSI pattern, suggesting that it
may be relevant to consider the heterogeneity of the tumors
when it comes to assessing the MSI status.
In the clinical study by Kim et al. [102], it was revealed
that previously treated metastatic GC patients whose tumors
were EBV+ respond particularly well to ICB. It has been
demonstrated that EBV+ gastric tumors have very dis-
tinctive molecular features, including amplification (also
overexpression) of PD-L1 and PD-L2, conspicuous intra-
tumoral or peritumoral immune cell infiltration, especially
of CD8+ T cells, and IFN-c-driven gene expression profile
(GEP) (Figure 1(d)) [14, 103, 104]. -ese results highlight
the potential of EBV positivity as the predictor of the re-
sponse to IC inhibitors in GC; however, more clinical evi-
dence needs to be added to validate its use in clinical settings.
Of note, the studies in GC show that MSI and EBV are
mutually exclusive biomarkers [102, 103].
Although tumor-infiltrating lymphocyte density, par-
ticularly that of infiltrating CD8+ T cells, is strongly asso-
ciated with ICB response in several cancer types [9, 48], this
has not been rigorously evaluated in GC. Some studies in
GC, however, have identified immune-related GEPs that
correlate with clinical benefit from ICB therapy, especially the
IFN-c-driven and T-cell-inflamed related gene signatures
(Supplementary Table 1). Accordingly, the KEYNOTE-059
trial found that all patients with a PD-L1 CPS >20 had high
T-cell-inflamed GEP scores. Elevated expression levels of
immune-related gene signatures, however, do not necessarily
predict ICB response as this may be influenced by other
parameters. -is is exemplified in the NCT02589496 clinical
trial [102], which revealed that gastric tumors with mesen-
chymal subtype, defined by elevated expression of an epi-
thelial-to-mesenchymal transition (EMT) gene signature, do
not respond to ICB despite exhibiting elevated levels of
immune signatures. Indeed, the mesenchymal phenotype has
been demonstrated to be a negative predictor of response to
ICB in other cancer types and a key determinant of poor
survival in GC [105, 106]. According to these results, com-
bination of several parameters may be a better strategy in
order to accurately predict the response to ICB in GC.
-e use in clinical practice of the approach known as
liquid biopsy to determine the response to ICB is highly
desirable since this is a noninvasive method that enables the
constant follow-up of patients undergoing therapy. With
liquid biopsy, for example, it is feasible to determine the
tumor mutational load through sequencing analysis of
blood-derived circulating tumor DNA (ctDNA). -e po-
tential of this approach has been demonstrated in a trial of 69
patients representing 23 different cancer types, concluding
that the number of mutations detected in ctDNA was
positively associated with ICB response [107]. Similar results
were found in a study in non-small cell lung cancer patients
treated with atezolizumab [108]. In GC, ctDNA sequencing
can reproduce tumor tissue exome sequencing andMSI PCR
testing to identify patients likely to respond to pem-
brolizumab. Even more importantly, posttreatment changes
in ctDNA predict both ICB response and progression in GC
[102]. -ese findings expand the possibilities of using liquid
biopsy in the clinic to perform evaluations of tumor mu-
tational load as the predictive biomarker of ICB response.
9.Helicobacter pylori Infection and Its
Potential Relevance in the Context of ICB
-e inflammatory response mounted against H. pylori
infection is characterized by a local upregulation in the
expression of a vast array of inflammatory mediators and
the recruitment of various populations of bone marrow-
derived cells to the gastric mucosa, including neutrophils,
macrophages, and dendritic, T, and B cells (Figure 1(a))
[109, 110]. H. pylori induces the expression of cytokines
such as interleukin (IL)-1β, tumor necrosis factor-α (TNF-
α), IL-6, IL-8, IFN-c, and the cyclooxygenase (COX)-2
enzyme [111–115], as well as the activation of the transcription
factor NF-kB [52, 116]. Most of these effector molecules have
pleiotropic effects, thus influencing the progression of H. py-
lori-induced carcinogenesis at different levels. One of the best-
studied inflammatory mediators in this context is IL-1β, which
exerts a proinflammatory function and acts as a strong in-
hibitor of the gastric acid secretion [112, 117].-e latter creates
a less hostile environment for H. pylori and other microbial
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communities lodged in the stomach. In fact, H. pylori-colo-
nized individuals with high-expression polymorphisms in the
IL-1β gene cluster, that is, IL-1β and its naturally occurring IL-1
receptor antagonist (IL-1RN), have increased risk for hypo-
chlorhydria, gastric atrophy, and distal GC [53, 118, 119]. IL-1β
per se is sufficient to induce gastric neoplasia in a mouse model
with stomach-specific transgenic overexpression of IL-1β,
which is mediated by activation of NF-kB and early re-
cruitment of myeloid-derived suppressor cells (MDSCs) to the
stomach [117]. Notwithstanding this, the bacterium generally
remains in the stomach of colonized individuals for life, in-
dicating that the immune response is ineffective to clear the
infection. In addition, the presence of inflammation for decades
supports the notion that the immune response is dysregulated
by H. pylori [110, 120–122]. -e mechanisms by which this
bacteriummodulates innate and adaptive immunity have been
reviewed elsewhere [50, 110].
Both in vitro and in vivo studies have reported that the
expression of some IC proteins in gastric epithelial and
activated T cells is upregulated upon H. pylori colonization,
presumably as part of the strategies to evade and subvert host
immune defenses (Figure 1(b)). -e upregulation of PD-L1
in gastric epithelial cells following H. pylori infection is
relatively well documented both in vivo and in vitro
[22–25, 123]. Some of the studies addressing this connection
have unraveled aspects underlying the induction and reg-
ulation of PD-L1 expression in response to H. pylori. For
example, it has been demonstrated that the induction of PD-
L1 in gastric epithelial cells by H. pylori requires its type 4
secretion system (T4SS), whose components activate the p38
MAPK pathway [25]. Importantly, studies in mouse models
conclude that the upregulation of PD-L1 results in increased
bacterial load, induction of Treg cells in the stomach, and
increased IL-10 in serum [25]. Elevated expression of PD-L1
in gastric epithelial cells may induce apoptosis of T cells
[24]. Also, the induction of PD-L1 expression in GC cells
cocultured with H. pylori is inhibited by miR-152 and miR-
200b [123]. Interestingly, PD-L1 expression is negatively
correlated with miR-152 and miR-200b levels in gastric
tumor tissues from human patients [123]. -e induction of
other IC molecules in the context of H. pylori infection has
also been reported. For example, a recent immunohisto-
chemistry study found higher levels of Gal-3 in the gastric
mucosa of patients with H. pylori infection, compared to
noninfected subjects [124]. Finally, H. pylori stimulation
resulted in a significant increase of Tim-3 in an in vitro
system [125]. Altogether, these observations support the
notion that IC protein induction in the context of H. pylori
infection might contribute to the establishment of a per-
sistent infection, which in turn favors the progression from
premalignant lesions to gastric adenocarcinoma through the
creation of an immunosuppressive microenvironment.
10. Conclusions
-e establishment of a suppressive TIME is a parameter that
greatly influences tumor progression. T-cell exhaustion,
through the expression of different ICs, is one of the most
salient manifestations of the suppressive TIME.-e immune-
editing process that takes place during GC initiation and
progression, from a proinflammatory state induced by
H. pylori or EBV infection towards a suppressive microen-
vironment, includes upregulation in the expression of ICs that
prevent T-cell-mediated elimination of tumor cells. -e fact
that this exhausted state can be reverted with the use of
monoclonal antibodies has revolutionized cancer treatment.
In the context of GC, the recent approval of the anti-PD-1,
pembrolizumab, for the treatment of advanced or recurrent
GC represents an important achievement since a large
number of patients are diagnosed at advanced stages, when
the probability of curing the disease is very limited. A major
hurdle, however, is the identification of biomarkers that can
be used in the clinic to stratify GC patients and personalize
ICB therapy. Until now, there are many promising bio-
markers that may be helpful as predictive criteria, but none of
them seem to be useful by themselves. Instead, clinical trials
reflect the requirement of standardizing an algorithm that
includes not one but several of these potential biomarkers,
such as PD-L1 expression, microsatellite instability (MSI),
MMR deficiency, EBV positivity, immune-related GEPs,
ctDNA mutational load scores, and mesenchymal subtype.
-e induction of ICs expression in response to H. pylori
infection is a very fascinating finding that may have im-
portant implications in gastric carcinogenesis and, therefore,
needs to be further explored. To date, very few studies have
addressed the molecular mechanisms underlying this re-
lation. A particularly relevant aspect is whether the in-
duction of ICs in the nonneoplastic gastric epithelium
colonized withH. pylori has an impact in the composition of
the microenvironment of manifest GC lesions. More spe-
cifically, it is important to know if the expression of ICs in
early stages of carcinogenesis favors the creation of a sup-
pressive inflammatory microenvironment, which facilitates
the growth and progression of invasive gastric tumors. High
expression of ICs and infiltration by effector T cells from
very early stages in the sequence of events that culminates
with GC could mean a better response to immunotherapy.
Ultimately, all this information may also serve as evidence in
favor of the use of ICB therapies in early stages of the disease.
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